Oxalo Therapeutics

Oxalo Therapeutics is a private, preclinical biotech founded in 2018 and spun out from the University of Chicago. The company is pioneering a novel, microbiome-inspired peptide therapeutic platform to treat primary hyperoxaluria and other oxalate-related pathologies by promoting oxalate secretion in the gut. With an experienced leadership team combining deep nephrology expertise and business acumen, Oxalo is targeting a high-unmet medical need in a defined orphan disease population, with potential applications in broader kidney stone prevention.

Microbiome-inspired peptide platform that mimics Oxalobacter formigenes to induce intestinal oxalate secretion for systemic oxalate removal.

In Primary Hyperoxaluria, Alnylam's RNAi therapy (lumasiran) is the approved competitor, setting a high efficacy bar. For broader kidney stones, competition includes generic dietary management and urinary modifiers (e.g., potassium citrate), but no targeted oxalate-lowering drug exists, representing a white space.